LONDON, Nov. 2, 2021 /PRNewswire/ — Smith+Nephew (LSE:SN,NYSE:SNN), the global medical technology business, today announces the introduction of its LEGION CONCELOC Cementless Total Knee System (TKS) and first completed surgical procedures.
CONCELOC Advanced Porous Titanium is a patented, proprietary, 3D printed porous structure technology first used in Smith+Nephew’s leading REDAPT™ Revision Hip System, launched in 2016. CONCELOC is created in a virtual environment and manufactured through 3D printing additive manufacturing to optimize its porous structure to promote bony ingrowth.1-4
“LEGION CONCELOC addresses the critical elements of the cementless total knee through its unique design. The asymmetrical keel is designed to help achieve immediate bone fixation, while the patented 3D printed structure of CONCELOC encourages biological ingrowth,” said Dr. Mathias Bostrom, an orthopaedic surgeon at the Hospital for Special Surgery in New York City, and one of the system’s designing surgeons. “I’m excited for how this technology may lead to improved operating room efficiency while eliminating many of the past and current challenges of cementless knee designs.”
Combining CONCELOC 3D printing technology with LEGION’s clinical success5-8 * treating over two million patients creates a unique, modern cementless knee implant. It serves a resurgent segment9 driven by the potential for better long-term fixation through biologic integration10, shorter operating times11, and the shift to Ambulatory Surgery Centers.12
“The launch of LEGION CONCELOC enables Smith+Nephew to enter a rapidly growing market in cementless knees,” said Skip Kiil, President of Global Orthopaedics at Smith+Nephew. “This proven technology allows us to leverage great clinical results of LEGION, modern 3D printing technology, our Real Intelligence technology suite, and new streamlined SYNC Performance Instruments to provide an economic solution that removes cement costs and time to knee procedures.”
The LEGION CONCELOC Cementless Total Knee System is now available in North America and will be introduced in various European and Asia Pacific markets once regulatory approvals are finalised.
- Smith + Nephew 2019. Technical Memo TM-19-067.
- Kienapfel H, Sprey C, Wilke A, Griss P. Implant fixation by bone ingrowth. J Arthroplasty. 1999;14(3):355-368.
- Bobyn J, Pilliar R, Cameron H, Weatherly G. The optimum pore size for the fixation of porous-surfaced metal implants by the ingrowth of bone. Clin Orthop Relat Res. 1980(150):263-270.
- Biologic fixation of additive manufactured CONCELOC Advanced Porous Titanium in a load-bearing animal model. White paper, 04741v2 April 2020
- Victor J, Ghijselings S, Tajdar F, et al. Total knee arthroplasty at 15-17 years: does implant design affect outcome? Int Orthop. 2014;38(2):235-241.
- Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) 2021. Hip, Knee & Shoulder Arthroplasty Annual Report.
- National Joint Registry for England, Wales, Northern Ireland and the Isle of Man. Hertfordshire, UK 2021. 18th Annual Report.
- McCalden RW, Hart GP, MacDonald SJ, Naudie DD, Howard JH, Bourne RB. Clinical Results and Survivorship of the GENESIS II Total Knee Arthroplasty at a Minimum of 15 Years. J Arthroplasty. 2017;32(7):2161-2166
- http://www.precisionreports.co/global-cementless-total-knee-arthroplasty-tka-market-18813794 [Accessed: 28th Oct 2021]
- Restrepo S, Smith EB, Hozack WJ. Excellent mid-term follow-up for a new 3D-printed cementless total knee arthroplasty. Bone Joint journal. 2021;103-B(6 Sup A):32-7
- Yayac M, Harrer S, Hozack WJ, Parvizi J, Courtney M. The use of cementless components does not signiﬁcantly increase procedural costs in total knee arthroplasty. J Arthroplasty. 2020;35:407-712
- DeCook CA. Outpatient joint arthoplasty: transitioning to the Ambulatory Surgery Center. J Arthroplasty. 2019; 34: S48-S50
* We thank the patients and staff of all the hospitals in England, Wales and Northern Ireland who have contributed data to the National Joint Registry. We are grateful to the Healthcare Quality Improvement Partnership (HQIP), the NJR Steering Committee and staff at the NJR Centre for facilitating this work. The views expressed represent those of the authors and do not necessarily reflect those of the National Joint Registry Steering Committee or the Health Quality Improvement Partnership (HQIP) who do not vouch for how the information is presented.
Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith+Nephew is a constituent of the FTSE100 (LSE:SN,NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.
™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.
SOURCE Smith & Nephew plc